The International Cannabis Policy Study (ICPS) is a project designed to evaluate the impact of cannabis policies at the national and provincial/state levels. The ICPS Project consists of annual, population-based surveys conducted in 6 countries: Canada and the United States (since 2018), Australia, and New Zealand (since 2021), and Germany and the United Kingdom (since 2022) with more than 300,000 respondents, including approximately 100,000 cannabis consumers.
The overall objective of the ICPS project is to understand the impact of cannabis policies, including the overall impact of legalization, as well as specific regulatory measures, such as product standards, retail policies, cannabis marketing, and public education. The ICPS surveys provide a comprehensive assessment of cannabis use, includes detailed patterns of consumption, purchasing, adverse outcomes, as well as attitudes and beliefs towards cannabis.
Recent papers from the ICPS study
Social norms for cannabis use following non-medical legalization in Canada.
Winfield-Ward L, Hammond D. American Journal of Preventive Medicine 2023; S0749-3797(23)00513-5.
Adverse outcomes of cannabis use in Canada, before and after legalization of non-medical cannabis: cross-sectional analysis of the international cannabis policy study.
Marquette A, Iraniparast M, Hammond D. British Medical Journal Open 2024; 14(1):e077908.
Legal status of recreational cannabis and self-reported substitution of cannabis for opioids or prescription pain medication in Canada and the United States.
Wadsworth E, Hines LA, Hammond D. Substance Abuse 2022; 43(1):943-948.
Cannabis and Mental Health: Adverse Outcomes and Self-Reported Impact of Cannabis Use by Mental Health Status.
Rup J, Freeman T, Perlman CP, Hammond D. Substance Use & Misuse 2022; 57(5):719-729.
Perceptions of the health risks of cannabis: estimates from national surveys in Canada and the United States, 2018-2019.
Goodman S, Hammond D. Health Education Research 2022; 37(2):61-78.
Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada.
Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Psychopharmacology. 2022; 239(5):1509-1519.
Cannabis and mental health: prevalence of use and modes of cannabis administration by mental health status.
Rup J, Freeman TP, Perlman C, Hammond D. Addictive Behaviors 2021; 121:106991.
Mental health and medical cannabis use among youth and young adults in Canada.
Wadsworth E, Leos-Toro C, Hammond D. Substance Use and Misuse 2020; 55(4): 582-589.
Perceived support for medical cannabis use among approved medical cannabis users in Canada.
Leos-Toro C, Shiplo S, Hammond D. Drug & Alcohol Review 2018; 37:627-636.
Medical Marijuana Use in Canada: Vapourization and Modes of Delivery.
Shiplo S, Asbridge M, Leatherdale SL, Hammond D. Harm Reduction Journal 2016; 107(3): e296–e302.
